Medication info
Telmisartan/ Rosuvastatin 80/20 mg

Telmisartan/ Rosuvastatin 80/20 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201907251 · Approved 2019.10.15 · Insurance code 657806780

Summary

Main use
Treatment of hypertension and dyslipidemia; reduction of cardiovascular risk and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
In a drug interaction study of the active ingredients in this medicine, telmisartan 80mg and rosuvastatin 20mg, in the presence of rosuvastatin, the Cmax of telmisartan was approximately 0.87-fold and its AUC was approximately 1.00-fold; in the presence of telmisartan, the Cmax of rosuvastatin increased approximately 1.71-fold and its AUC increased approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and closely monitor the patient. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; reduction of cardiovascular risk and inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of damage to end organs
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This drug is prescribed for patients who need to use Telmisartan and Rosuvastatin simultaneously. Telmisartan is primarily used to treat essential hypertension and reduce the risk of cardiovascular disease. It specifically reduces the risk of myocardial infarction, stroke, and death from cardiovascular diseases in high-risk patients aged over 55 years who cannot use ACE inhibitors. Rosuvastatin Calcium is used in conjunction with a diet for primary and familial hypercholesterolemia, mixed dyslipidemia, etc., and it lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis. It also reduces the risk of cardiovascular diseases, especially helping to lower the risk of stroke, myocardial infarction, and vascular revascularization in high-risk patients with elevated high-sensitivity C-reactive protein levels. Therefore, this drug is used to improve cardiovascular health through blood pressure and lipid management.

How to take

Adult dose

In a drug interaction study of the active ingredients in this medicine, telmisartan 80mg and rosuvastatin 20mg, in the presence of rosuvastatin, the Cmax of telmisartan was approximately 0.87-fold and its AUC was approximately 1.00-fold; in the presence of telmisartan, the Cmax of rosuvastatin increased approximately 1.71-fold and its AUC increased approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and closely monitor the patient. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. It is not to be administered to individuals allergic to this drug, pregnant or breastfeeding women, and fertile women not using appropriate contraception. It is safe not to use in patients with severe liver damage or those with bile flow problems. In patients with severe renal impairment or when combined with certain medications, this drug should not be used. Elderly patients or those with elevated blood potassium levels, or those with slightly impaired liver function must use this drug cautiously, requiring regular blood tests and monitoring of health status. This drug may lead to muscle-related side effects such as myalgia or muscle weakness, so any unusual symptoms should be reported to a physician immediately. If symptoms such as severe myalgia, muscle weakness, muscle cramps occur, or if blood tests show significantly elevated muscle damage markers, the medication should be discontinued. Since liver function abnormalities may occur, regular liver function tests should be conducted while taking this drug. Be aware that this drug may interact with other medications; inform your physician or pharmacist of any other medications being taken. Due to its potent hypotensive effect, be cautious of symptoms such as low blood pressure, dizziness, and fainting. Avoid alcohol consumption while taking this drug, especially if there is a history of liver disease. Women of childbearing potential must use proper contraception while taking this drug, and must discontinue immediately upon confirmation of pregnancy. Breastfeeding women are advised not to take this drug; if it must be taken, breastfeeding should be stopped. This drug's safety and efficacy have not been established in children, so its use is generally not recommended. In case of overdose, symptoms such as low blood pressure, dizziness, and acute renal failure may occur, requiring immediate medical attention. During treatment with this drug, be cautious while driving or operating dangerous machinery, as dizziness or drowsiness may occur. Store in a place out of reach of children and do not transfer to another container.

Side effects

Headache, positional vertigo, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reactions, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver dysfunction, hepatic impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lower back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscular weakness, ocular muscle weakness, hypotension, tachycardia, bradycardia, acute renal failure, blood pressure reduction, shock, loss of consciousness, liver dysfunction, jaundice, anaphylactic-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, hypovolemia due to decreased blood volume, hypotension due to depletion of blood volume and sodium, gastrointestinal bleeding, acute renal failure, increased serum potassium, increased serum creatinine, failure to control blood pressure, syncope due to blood pressure reduction, loss of consciousness, liver dysfunction, jaundice, angioedema, intestinal angioedema, interstitial lung disease, fatal and non-fatal liver failure, increased HbA1c and fasting blood glucose levels, hyperglycemia, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, severe muscular weakness, ocular muscle weakness, acute renal failure, musculoskeletal toxicity, myalgia, myopathy, rhabdomyolysis, increased CK levels, elevated transaminases, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscular weakness, ocular muscle weakness, hypotension, tachycardia, bradycardia, acute renal failure, blood pressure reduction, shock, loss of consciousness, liver dysfunction, jaundice, anaphylactic-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a sealed container to prevent exposure to air or moisture, and it should be kept at a temperature between 1°C and 30°C. Therefore, it is important to store it in a cool, dry place until use.

Appearance and packaging

Appearance

White oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.